Literature DB >> 10451073

Baseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies.

M R Cohen1, D J Reda, D O Clegg.   

Abstract

OBJECTIVE: To determine differences in disease onset, extent, and manifestations of psoriasis among patients with active, inflammatory psoriatic arthritis (PsA), and to examine relationships that may exist between psoriasis and PsA.
METHODS: Baseline demographic, clinical, and laboratory data were analyzed from 221 patients enrolled in a multicenter cooperative study, and relationships between measures of psoriasis and PsA were determined.
RESULTS: Mean percentage of body surface area (BSA) affected by psoriasis was modest (12+/-17), and mean severity of erythema, induration, and scaling was moderate (4.9+/-2.1 on a 0-9 scale). Spanish Americans tended to have a higher mean percentage of BSA (18.5%) than Caucasians (11%; p = 0.067), as well as higher target lesion severity (5.55 vs. 4.84; p = 0.077). Patients with psoriatic nail disease (180/221, 81%) had significantly greater number of involved distal interphalangeal (DIP) joints (p = 0.004). There were no other significant associations of skin pattern or regional involvement with PsA.
CONCLUSION: Patients with active PsA have generally mild skin disease, and baseline relationships between psoriasis and PsA tend to be weak except for nail involvement and DIP joint activity.

Entities:  

Mesh:

Year:  1999        PMID: 10451073

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  16 in total

Review 1.  Update on the natural history and systemic treatment of psoriasis.

Authors:  Stephen K Richardson; Joel M Gelfand
Journal:  Adv Dermatol       Date:  2008

2.  Relationship between psoriatic arthritis and moderate-severe psoriasis: analysis of a series of 166 psoriatic arthritis patients selected from a hospital population.

Authors:  Noemi Busquets-Pérez; Jesus Rodriguez-Moreno; Carmen Gómez-Vaquero; Joan M Nolla-Solé
Journal:  Clin Rheumatol       Date:  2011-06-24       Impact factor: 2.980

Review 3.  Diagnosis and management of psoriatic arthritis.

Authors:  John Brockbank; Dafna Gladman
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Comparative microscopic analysis of nail clippings from patients with cutaneous psoriasis and psoriatic arthritis.

Authors:  Gabriela Poglia Fonseca; Betina Werner; Gabriela Seidel; Henrique Luiz Staub
Journal:  An Bras Dermatol       Date:  2017 Jan-Feb       Impact factor: 1.896

5.  Rheumatic manifestations of psoriasis.

Authors:  H A Sadek; A M Abdel-Nasser; T A El-Amawy; S Z Hassan
Journal:  Clin Rheumatol       Date:  2006-05-03       Impact factor: 2.980

Review 6.  Traditional and newer therapeutic options for psoriatic arthritis: an evidence-based review.

Authors:  Dafna D Gladman
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 7.  Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors.

Authors:  P J Mease
Journal:  Ann Rheum Dis       Date:  2002-04       Impact factor: 19.103

8.  Update of the management of chronic psoriasis: new approaches and emerging treatment options.

Authors:  Philip M Laws; Helen S Young
Journal:  Clin Cosmet Investig Dermatol       Date:  2010-04-21

9.  A randomised placebo controlled trial of delipidated, deglycolipidated Mycobacterium vaccae as immunotherapy for psoriatic arthritis.

Authors:  N Dalbeth; S Yeoman; J L Dockerty; J Highton; E Robinson; P L Tan; D Herman; F M McQueen
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

10.  Infliximab in the treatment of plaque type psoriasis.

Authors:  Rosita Saraceno; Andrea Saggini; Lucia Pietroleonardo; Sergio Chimenti
Journal:  Clin Cosmet Investig Dermatol       Date:  2009-04-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.